## Mauro Giulio Papotti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3694674/publications.pdf

Version: 2024-02-01

305 papers 20,864 citations

75 h-index 132 g-index

309 all docs

309 docs citations

times ranked

309

16109 citing authors

#	Article	IF	Citations
1	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. JAMA Oncology, 2016, 2, 1023.	7.1	1,192
2	Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. New England Journal of Medicine, 2007, 356, 2372-2380.	27.0	679
3	Ghrelin, a Natural GH Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5083-5083.	3.6	603
4	Poorly Differentiated Thyroid Carcinoma: The Turin Proposal for the Use of Uniform Diagnostic Criteria and an Algorithmic Diagnostic Approach. American Journal of Surgical Pathology, 2007, 31, 1256-1264.	3.7	521
5	Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1169-1174.	3.6	428
6	Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, 2022, 33, 27-63.	9.0	388
7	Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet, The, 2001, 357, 1644-1650.	13.7	379
8	Growth Hormone Secretagogue Binding Sites in Peripheral Human Tissues1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3803-3807.	3.6	369
9	Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer, 2006, 107, 1589-1596.	4.1	364
10	Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. European Journal of Pharmacology, 2002, 440, 235-254.	<b>3.</b> 5	324
11	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Towards a Standardized Approach to the Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors and Their Prognostic Stratification. Neuroendocrinology, 2009, 90, 162-166.	2.5	313
12	Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1300-1308.	3.6	306
13	Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncology, The, 2008, 9, 543-549.	10.7	284
14	Identification, Characterization, and Biological Activity of Specific Receptors for Natural (Ghrelin) and Synthetic Growth Hormone Secretagogues and Analogs in Human Breast Carcinomas and Cell Lines1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1738-1745.	3.6	277
15	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	3.6	274
16	Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Modern Pathology, 2007, 20, 1172-1182.	5.5	266
17	A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1599-1610.	1.1	234
18	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocrine Pathology, 2022, 33, 115-154.	9.0	227

#	Article	IF	CITATIONS
19	Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 377-407.	1.1	212
20	The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer, 2012, 76, 1-18.	2.0	206
21	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	1.1	205
22	PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 499-519.	1.1	203
23	Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns. Cancer, 2004, 100, 950-957.	4.1	198
24	Cytological features of "noninvasive follicular thyroid neoplasm with papillary-like nuclear features―and their correlation with tumor histology. Human Pathology, 2016, 54, 134-142.	2.0	190
25	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. Journal of Thoracic Oncology, 2017, 12, 194-207.	1.1	186
26	Ghrelin, a Natural GH Secretagogue Produced by the Stomach, Induces Hyperglycemia and Reduces Insulin Secretion in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5083-5083.	3.6	183
27	The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee. Journal of Thoracic Oncology, 2020, 15, 1409-1424.	1.1	182
28	Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. European Journal of Endocrinology, 2004, 150, 173-184.	3.7	181
29	RAS Mutations Are the Predominant Molecular Alteration in Poorly Differentiated Thyroid Carcinomas and Bear Prognostic Impact. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4735-4741.	3.6	181
30	Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Human Pathology, 2002, 33, 175-182.	2.0	176
31	SDHB/SDHA immunohistochemistry in pheochromocytomas and paragangliomas: a multicenter interobserver variation analysis using virtual microscopy: a Multinational Study of the European Network for the Study of Adrenal Tumors (ENS@T). Modern Pathology, 2015, 28, 807-821.	5 <b>.</b> 5	176
32	Obestatin Promotes Survival of Pancreatic $\hat{l}^2$ -Cells and Human Islets and Induces Expression of Genes Involved in the Regulation of $\hat{l}^2$ -Cell Mass and Function. Diabetes, 2008, 57, 967-979.	0.6	173
33	Ki-67 Antigen in Lung Neuroendocrine Tumors: Unraveling a Role in Clinical Practice. Journal of Thoracic Oncology, 2014, 9, 273-284.	1.1	162
34	Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer, 1991, 67, 663-672.	4.1	161
35	Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Research and Treatment, 2016, 157, 363-371.	2.5	156
36	RET/PTC Activation in Hyalinizing Trabecular Tumors of the Thyroid. American Journal of Surgical Pathology, 2000, 24, 1615-1621.	3.7	152

#	Article	IF	CITATIONS
37	Ghrelin Secretion Is Inhibited by Either Somatostatin or Cortistatin in Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 4829-4832.	3.6	152
38	Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Modern Pathology, 2010, 23, 1269-1278.	5.5	145
39	Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocrine-Related Cancer, 2010, 17, 445-453.	3.1	138
40	Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential. Modern Pathology, 2005, 18, 541-546.	5.5	131
41	International Histopathology Consensus for Unilateral Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 42-54.	3.6	127
42	î"Np63 (p40) and Thyroid Transcription Factor-1 Immunoreactivity on Small Biopsies or Cellblocks for Typing Non-small Cell Lung Cancer: A Novel Two-Hit, Sparing-Material Approach. Journal of Thoracic Oncology, 2012, 7, 281-290.	1.1	126
43	Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1300-1308.	3.6	125
44	Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fineâ€needle aspiration cytology. Cancer, 2011, 117, 3416-3423.	4.1	124
45	The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?. Journal of Thoracic Oncology, 2022, 17, 200-213.	1.1	124
46	Ghrelin Expression in Fetal, Infant, and Adult Human Lung. Journal of Histochemistry and Cytochemistry, 2002, 50, 1013-1021.	2.5	123
47	Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clinical Endocrinology, 2001, 54, 641-649.	2.4	122
48	Ghrelin-Producing Endocrine Tumors of the Stomach and Intestine. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5052-5059.	3.6	121
49	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. European Urology, 2014, 65, 832-838.	1.9	121
50	Apocrine carcinoma of the skin. A clinicopathologic, Immunocytochemical, and ultrastructural study. Cancer, 1993, 71, 375-381.	4.1	118
51	Ghrelin in Fetal Thyroid and Follicular Tumors and Cell Lines. American Journal of Pathology, 2003, 162, 645-654.	3.8	118
52	Expression of Apocrine Differentiation Markers in Neuroendocrine Breast Carcinomas of Aged Women. Modern Pathology, 2001, 14, 768-776.	5.5	112
53	Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology, 2009, 55, 535-543.	2.9	110
54	Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Seminars in Diagnostic Pathology, 2010, 27, 69-76.	1.5	108

#	Article	IF	Citations
55	ELOVL5 Mutations Cause Spinocerebellar Ataxia 38. American Journal of Human Genetics, 2014, 95, 209-217.	6.2	107
56	Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria—What has changed and why?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 519-531.	2.8	106
57	Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 439, 787-797.	2.8	105
58	Hyalinizing Trabecular Tumors of the Thyroid Gland are Almost all Benign. American Journal of Surgical Pathology, 2008, 32, 1877-1889.	3.7	105
59	Noninvasive follicular thyroid neoplasm with papillaryâ€like nuclear features (NIFTP): A changing paradigm in thyroid surgical pathology and implications for thyroid cytopathology. Cancer Cytopathology, 2016, 124, 616-620.	2.4	105
60	Classification of pulmonary neuroendocrine tumors: new insights. Translational Lung Cancer Research, 2017, 6, 513-529.	2.8	104
61	The Antiproliferative Effect of Synthetic Peptidyl GH Secretagogues in Human CALU-1 Lung Carcinoma Cells. Endocrinology, 2002, 143, 484-491.	2.8	103
62	RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 370-379.	3.6	99
63	The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine–endocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 499-506.	2.8	97
64	Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Modern Pathology, 2009, 22, 709-717.	<b>5.</b> 5	91
65	The Weiss Score and Beyondâ€"Histopathology for Adrenocortical Carcinoma. Hormones and Cancer, 2011, 2, 333-340.	4.9	91
66	Cytologic Features of Poorly Differentiated †Insular' Carcinoma of the Thyroid, as Revealed by Fine-Needle Aspiration Biopsy. American Journal of Clinical Pathology, 1990, 94, 687-692.	0.7	89
67	Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms. Endocrine Pathology, 2018, 29, 150-168.	9.0	89
68	Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocrine Pathology, 2022, 33, 155-196.	9.0	87
69	Chromogranin A Expression in Patients With Hormone Na $\tilde{\mathbb{A}}^-$ ve Prostate Cancer Predicts the Development of Hormone Refractory Disease. Journal of Urology, 2007, 178, 838-843.	0.4	86
70	Review Article: A Reevaluation of the Clinical Significance of Histological Subtyping of Nonâ€"Small-Cell Lung Carcinoma: Diagnostic Algorithms in the Era of Personalized Treatments. International Journal of Surgical Pathology, 2009, 17, 206-218.	0.8	84
71	Mammalian target of rapamycin signaling activation patterns in neuroendocrine tumors of the lung. Endocrine-Related Cancer, 2010, 17, 977-987.	3.1	84
72	BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. Journal of Thoracic Oncology, 2016, 11, 2006-2017.	1.1	83

#	Article	IF	CITATIONS
73	Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors. Clinical Cancer Research, 2008, 14, 1059-1064.	7.0	81
74	Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypical Variant Exhibiting Malignant Behavior. American Journal of Surgical Pathology, 2010, 34, 973-983.	3.7	81
75	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology, 2017, 12, 1654-1663.	1.1	81
76	Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI). Abdominal Radiology, 2019, 44, 1883-1893.	2.1	80
77	Obestatin regulates adipocyte function and protects against dietâ€induced insulin resistance and inflammation. FASEB Journal, 2012, 26, 3393-3411.	0.5	79
78	Unacylated ghrelin and obestatin increase islet cell mass and prevent diabetes in streptozotocin-treated newborn rats. Journal of Molecular Endocrinology, 2010, 45, 9-17.	2.5	78
79	Immunocytochemistry for predictive biomarker testing in lung cancer cytology. Cancer Cytopathology, 2019, 127, 325-339.	2.4	78
80	Ki67 proliferative index of the neuroendocrine component drives MANEC prognosis. Endocrine-Related Cancer, 2018, 25, 583-593.	3.1	77
81	Large Cell Neuroendocrine Carcinoma of the Gallbladder. American Journal of Surgical Pathology, 2000, 24, 1424-1428.	3.7	76
82	Diagnostic and prognostic role of steroidogenic factor 1 in adrenocortical carcinoma: a validation study focusing on clinical and pathologic correlates. Human Pathology, 2013, 44, 822-828.	2.0	76
83	Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study. BMC Cancer, 2014, 14, 184.	2.6	76
84	The Reticulin Algorithm for Adrenocortical Tumor Diagnosis. American Journal of Surgical Pathology, 2013, 37, 1433-1440.	3.7	75
85	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	3.7	75
86	Cell Membrane Reactivity of MIB-1 Antibody to Ki67 in Human Tumors: Fact or Artifact?. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 220-223.	1.2	74
87	Endocrine Activities of Cortistatin-14 and Its Interaction with GHRH and Ghrelin in Humans. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3783-3790.	3.6	72
88	Galectin-3 expression in parathyroid carcinoma: immunohistochemical study of 26 cases. Human Pathology, 2005, 36, 908-914.	2.0	71
89	Bone Sialoprotein Is Predictive of Bone Metastases in Resectable Non–Small-Cell Lung Cancer: A Retrospective Case-Control Study. Journal of Clinical Oncology, 2006, 24, 4818-4824.	1.6	69
90	Validation of the prognostic role of the "Helsinki Score―in 225 cases of adrenocortical carcinoma. Human Pathology, 2017, 62, 1-7.	2.0	69

#	Article	IF	Citations
91	Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clinical Cancer Research, 2009, 15, 7547-7552.	7.0	68
92	The Roles of Multiparametric Magnetic Resonance Imaging, PCA3 and Prostate Health Index—Which is the Best Predictor of Prostate Cancer after a Negative Biopsy?. Journal of Urology, 2014, 192, 60-66.	0.4	68
93	Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma. Modern Pathology, 2014, 27, 1246-1254.	<b>5.</b> 5	67
94	Ki-67 labeling index of neuroendocrine tumors of the lung has a high level of correspondence between biopsy samples and surgical specimens when strict counting guidelines are applied. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 153-164.	2.8	67
95	Ribonucleotide Reductase Large Subunit ( <i>RRM1</i> ) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clinical Cancer Research, 2012, 18, 3452-3461.	7.0	64
96	Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 713-720.	2.8	64
97	Effects of Octreotide Treatment on the Proliferation and Apoptotic Index of GH-Secreting Pituitary Adenomas. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5194-5200.	3.6	62
98	Poorly Differentiated Thyroid Carcinoma: Diagnostic Features and Controversial Issues. Endocrine Pathology, 2008, 19, 150-155.	9.0	62
99	Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network. BMC Cancer, 2009, 9, 388.	2.6	62
100	NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target. International Journal of Molecular Sciences, 2020, 21, 753.	4.1	62
101	Poorly Differentiated Thyroid Carcinoma: 5ÂYears after the 2004 WHO Classification of Endocrine Tumours. Endocrine Pathology, 2010, 21, 1-6.	9.0	56
102	Molecular Pathology of Poorly Differentiated and Anaplastic Thyroid Cancer: What Do Pathologists Need to Know?. Endocrine Pathology, 2021, 32, 63-76.	9.0	55
103	Oncocytic Adrenocortical Tumors. American Journal of Surgical Pathology, 2011, 35, 1882-1893.	3.7	52
104	The genetic landscape of breast carcinomas with neuroendocrine differentiation. Journal of Pathology, 2017, 241, 405-419.	4.5	52
105	Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 124-133.	1.1	52
106	Correlative Immunohistochemical and Reverse Transcriptase Polymerase Chain Reaction Analysis of Somatostatin Receptor Type 2 in Neuroendocrine Tumors of the Lung. Diagnostic Molecular Pathology, 2000, 9, 47-57.	2.1	52
107	Human ASH1 expression in prostate cancer with neuroendocrine differentiation. Modern Pathology, 2008, 21, 700-707.	5.5	51
108	î"Np63 (p40) Distribution Inside Lung Cancer. International Journal of Surgical Pathology, 2013, 21, 229-239.	0.8	51

#	Article	IF	Citations
109	MicroRNA expression patterns in adrenocortical carcinoma variants and clinical pathologic correlations. Human Pathology, 2014, 45, 1555-1562.	2.0	50
110	The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgenâ€deprivation therapy. Prostate, 2010, 70, 718-726.	2.3	49
111	Frequent RET Rearrangements in Thyroid Papillary Microcarcinoma Detected by Interphase Fluorescence In Situ Hybridization. Laboratory Investigation, 2001, 81, 1639-1645.	3.7	48
112	Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 183-8.	2.8	48
113	Heterogeneity of Large Cell Carcinoma of the Lung. American Journal of Clinical Pathology, 2011, 136, 773-782.	0.7	48
114	Ghrelin and the Endocrine Pancreas. Endocrine, 2003, 22, 19-24.	2.2	46
115	Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma. European Journal of Endocrinology, 2002, 147, 515-521.	3.7	45
116	Steroid hormone receptor in pleural solitary fibrous tumours and CD34+ progenitor stromal cells. Journal of Pathology, 2002, 198, 252-257.	4.5	45
117	ldentification of MicroRNAs Differentially Expressed in Lung Carcinoid Subtypes and Progression. Neuroendocrinology, 2015, 101, 246-255.	2.5	45
118	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. Endocrine Pathology, 2018, 29, 137-149.	9.0	45
119	Oxytocin and oxytocin-analogue F314 inhibit cell proliferation and tumor growth of rat and mouse mammary carcinomas., 1996, 66, 817-820.		44
120	Chromogranin A gene expression in non-small cell lung carcinomas. , 1998, 186, 151-156.		44
121	Cathepsin K Is Selectively Expressed in the Stroma of Lung Adenocarcinoma but Not in Bronchioloalveolar Carcinoma. American Journal of Clinical Pathology, 2006, 125, 847-854.	0.7	44
122	RFamide Peptides 43RFa and 26RFa Both Promote Survival of Pancreatic $\hat{l}^2$ -Cells and Human Pancreatic Islets but Exert Opposite Effects on Insulin Secretion. Diabetes, 2014, 63, 2380-2393.	0.6	44
123	Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. Human Pathology, 2015, 46, 1799-1807.	2.0	44
124	Morphologic and molecular classification of lung neuroendocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 5-19.	2.8	44
125	Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Translational Lung Cancer Research, 2013, 2, 372-81.	2.8	44
126	Somatostatin Receptors and Their Interest in Diagnostic Pathology. Endocrine Pathology, 2004, 15, 275-292.	9.0	43

#	Article	IF	CITATIONS
127	Neuro-endocrine tumours of the lung. A review of relevant pathological and molecular data. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 51-59.	2.8	43
128	Brain–gut communication: cortistatin, somatostatin and ghrelin. Trends in Endocrinology and Metabolism, 2007, 18, 246-251.	7.1	42
129	Obestatin in human neuroendocrine tissues and tumours: expression and effect on tumour growth. Journal of Pathology, 2009, 218, 458-466.	4.5	42
130	Morphology and a Limited Number of Immunohistochemical Markers May Efficiently Subtype Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, e141-e142.	1.6	41
131	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	2.5	41
132	Potential Diagnostic and Prognostic Role of Microenvironment in Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2019, 14, 1458-1471.	1.1	41
133	Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocrine Pathology, 2021, 32, 192-210.	9.0	41
134	Classification of lung neuroendocrine tumors: lights and shadows. Endocrine, 2015, 50, 315-319.	2.3	40
135	Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features (NIFTP): Achieving Better Agreement By Refining Diagnostic Criteria. Clinics, 2018, 73, e576.	1.5	40
136	The Antiproliferative Effect of Synthetic Peptidyl GH Secretagogues in Human CALU-1 Lung Carcinoma Cells. Endocrinology, 2002, 143, 484-491.	2.8	40
137	Papillary and follicular thyroid carcinomas with an insular component. Cancer, 1994, 74, 2599-2600.	4.1	39
138	Hexarelin Protects H9c2 Cardiomyocytes from Doxorubicin-Induced Cell Death. Endocrine, 2001, 14, 113-119.	2.2	39
139	Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours. Journal of Pathology, 2005, 207, 336-345.	4.5	39
140	Large cell carcinoma of the lung: A tumor in search of an author. A clinically oriented critical reappraisal. Lung Cancer, 2015, 87, 226-231.	2.0	39
141	PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid. Modern Pathology, 2019, 32, 1734-1743.	5 <b>.</b> 5	38
142	Recent advances in the molecular landscape of lung neuroendocrine tumors. Expert Review of Molecular Diagnostics, 2019, 19, 281-297.	3.1	38
143	Ultrastructural Features of Neuroendocrine Differentiated Carcinomas of the Breast. Ultrastructural Pathology, 1990, 14, 321-334.	0.9	37
144	Molecular alterations of neuroendocrine tumours of the lung. Histopathology, 2018, 72, 142-152.	2.9	37

#	Article	IF	Citations
145	Diagnostic cytological features of neuroendocrine differentiated carcinoma of the breast. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1998, 433, 217-222.	2.8	36
146	Neuroendocrine neoplasms of the appendix, colon and rectum. Pathologica, 2021, 113, 19-27.	3.4	36
147	Subtyping Non–Small Cell Lung Cancer. International Journal of Surgical Pathology, 2013, 21, 326-336.	0.8	35
148	The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progressionâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 631-639.	1.4	35
149	Thyroglobulin mRNA expression helps to distinguish anaplastic carcinoma from angiosarcoma of the thyroid. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 635-642.	2.8	34
150	Diagnostic role of galectin-3 in follicular thyroid tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 309-312.	2.8	33
151	Assessment of VAV2 Expression Refines Prognostic Prediction in Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3491-3498.	3.6	33
152	High interlaboratory and interobserver agreement of somatostatin receptor immunohistochemical determination and correlation with response to somatostatin analogs. Human Pathology, 2018, 72, 144-152.	2.0	32
153	Papillary thyroid carcinoma presenting as a solitary soft tissue arm metastasis in an elderly hyperthyroid patient. Case report and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 448, 857-861.	2.8	31
154	A hybrid deep learning approach for gland segmentation in prostate histopathological images. Artificial Intelligence in Medicine, 2021, 115, 102076.	6.5	31
155	Diagnostic Controversies in Vascular Proliferations of the Thyroid Gland. Endocrine Pathology, 2008, 19, 175-183.	9.0	30
156	Precision medicine in age-specific non-small-cell-lung-cancer patients: Integrating biomolecular results into clinical practice—A new approach to improve personalized translational research. Lung Cancer, 2017, 107, 84-90.	2.0	30
157	Prognostic Factors of Clinical Interest in Poorly Differentiated Carcinomas of the Thyroid. Endocrine Pathology, 2004, 15, 313-318.	9.0	29
158	Confocal microscope analysis and tridimensional reconstruction of papillary thyroid carcinoma nuclei. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 350-355.	2.8	29
159	Emerging drugs for adrenocortical carcinoma. Expert Opinion on Emerging Drugs, 2008, 13, 497-509.	2.4	29
160	Lung neuroendocrine tumors: pathological characteristics. Journal of Thoracic Disease, 2017, 9, S1442-S1447.	1.4	29
161	Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2226-2231.	7.1	29
162	Pathology of the Adrenal Cortex: a Reappraisal of the Past 25ÂYears Focusing on Adrenal Cortical Tumors. Endocrine Pathology, 2014, 25, 35-48.	9.0	28

#	Article	IF	CITATIONS
163	Placenta histopathology in SARS-CoV-2 infection: analysis of a consecutive series and comparison with control cohorts. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 715-728.	2.8	28
164	Galectin-3 and Ki-67 Expression in Multiglandular Parathyroid Lesions. American Journal of Clinical Pathology, 2006, 126, 59-66.	0.7	27
165	The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2011, 458, 393-402.	2.8	27
166	Extrapulmonary neuroendocrine small and large cell carcinomas: a review of controversial diagnostic and therapeutic issues. Human Pathology, 2014, 45, 665-673.	2.0	27
167	What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms?. Seminars in Diagnostic Pathology, 2015, 32, 469-479.	1.5	27
168	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. Journal of Thoracic Oncology, 2018, 13, 1750-1761.	1.1	27
169	Pancreatic Oncocytic Endocrine Tumors. Acta Cytologica, 1996, 40, 742-746.	1.3	26
170	Human ASH-1 Promotes Neuroendocrine Differentiation in Androgen Deprivation Conditions and Interferes With Androgen Responsiveness in Prostate Cancer Cells. Prostate, 2013, 73, 1241-1249.	2.3	26
171	Dissecting Pulmonary Large-Cell Carcinoma by Targeted Next Generation Sequencing of Several Cancer Genes Pushes Genotypic-Phenotypic Correlations to Emerge. Journal of Thoracic Oncology, 2015, 10, 1560-1569.	1.1	26
172	Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy. Hypertension Research, 2020, 43, 500-510.	2.7	26
173	Goblet cell carcinoids and other mixed neuroendocrine/nonneuroendocrine neoplasms. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 61-69.	2.8	25
174	Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. Molecular and Cellular Endocrinology, 2014, 382, 1-7.	3.2	25
175	Expression Analysis of Genes Involved in DNA Repair or Synthesis in Mixed Neuroendocrine/Nonneuroendocrine Carcinomas. Neuroendocrinology, 2015, 101, 151-160.	2.5	25
176	Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. Human Pathology, 2016, 58, 113-122.	2.0	25
177	Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome. Journal of Thoracic Oncology, 2014, 9, 1540-1546.	1.1	24
178	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. Oncotarget, 2016, 7, 21190-21198.	1.8	24
179	RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. Molecular and Cellular Endocrinology, 2015, 401, 105-110.	3.2	23
180	Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Annals of the Rheumatic Diseases, 2019, 78, 1004-1006.	0.9	23

#	Article	IF	Citations
181	Impact of COVIDâ€19 lockdown measures on oncological surgical activity: Analysis of the surgical pathology caseload of a tertiary referral hospital in Northwestern Italy. Journal of Surgical Oncology, 2021, 123, 24-31.	1.7	23
182	Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer. Oncotarget, 2016, 7, 14394-14404.	1.8	23
183	Methodological Considerations Regarding the Use of Galectin-3 Expression Analysis in Preoperative Evaluation of Thyroid Nodules. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 950-950.	3.6	22
184	Utilility of flow cytometry as ancillary study to improve the cytologic diagnosis of thyroid lymphomas. Cytometry Part B - Clinical Cytometry, 2015, 88, 320-329.	1.5	22
185	Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 718-728.	1.1	22
186	ACTH-producing tumorlets and carcinoids of the lung: clinico-pathologic study of 63 cases and review of the literature. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 587-597.	2.8	22
187	Role of Immunocytochemistry in the Cytological Diagnosis of Pulmonary Tumors. Acta Cytologica, 2020, 64, 16-29.	1.3	22
188	Automated assessment of glomerulosclerosis and tubular atrophy using deep learning. Computerized Medical Imaging and Graphics, 2021, 90, 101930.	5.8	22
189	The story of poorly differentiated thyroid carcinoma: From Langhans' description to the Turin proposal via Juan Rosai. Seminars in Diagnostic Pathology, 2016, 33, 277-283.	1.5	21
190	Cathepsin K Is Selectively Expressed in the Stroma of Lung Adenocarcinoma but not in Bronchioloalveolar Carcinoma. American Journal of Clinical Pathology, 2005, 125, 847-854.	0.7	21
191	Somatostatin Octapeptides (Lanreotide, Octreotide, Vapreotide, and Their Analogs) Share the Growth Hormone–Releasing Peptide Receptor in the Human Pituitary Gland. Endocrine, 2001, 14, 029-033.	2.2	20
192	Targeting the Ghrelin Receptor: Orally Active GHS and Cortistatin Analogs. Endocrine, 2003, 22, 13-18.	2.2	20
193	A Practical Diagnostic Approach to Solid/Trabecular Nodules in the Thyroid. Endocrine Pathology, 2008, 19, 75-81.	9.0	20
194	Androgen deprivation modulates gene expression profile along prostate cancer progression. Human Pathology, 2016, 56, 81-88.	2.0	20
195	Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, 125, 2245-2253.	1.4	19
196	Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2016, 11, 504-515.	1.1	19
197	PD-1 (PDCD1) promoter methylation in Merkel cell carcinoma: prognostic relevance and relationship with clinico-pathological parameters. Modern Pathology, 2019, 32, 1359-1372.	5.5	19
198	Proton pump inhibitors promote the growth of androgen-sensitive prostate cancer cells through ErbB2, ERK1/2, PI3K/Akt, GSK-3Î <sup>2</sup> signaling and inhibition of cellular prostatic acid phosphatase. Cancer Letters, 2019, 449, 252-262.	7.2	19

#	Article	IF	Citations
199	Intriguing Case: Argyrophilic Neuroendocrine Carcinoma of the Male Breast. Ultrastructural Pathology, 1993, 17, 115-120.	0.9	18
200	Myxoid adrenocortical adenoma with a pseudoglandular pattern. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 445, 414-418.	2.8	18
201	Detection of human androgen receptor mRNA in hepatocellular carcinoma by <i>in situ</i> hybridisation. Liver, 1994, 14, 213-219.	0.1	18
202	Spread through air spaces (STAS) is a predictor of poor outcome in atypical carcinoids of the lung. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 475, 325-334.	2.8	18
203	Fully automated quantitative assessment of hepatic steatosis in liver transplants. Computers in Biology and Medicine, 2020, 123, 103836.	7.0	18
204	Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Human Pathology, 2021, 110, 50-61.	2.0	18
205	The Diagnosis of Hyalinizing Trabecular Tumor: A Difficult and Controversial Thyroid Entity. Head and Neck Pathology, 2020, 14, 778-784.	2.6	17
206	Quantitation of somatostatin receptor type 2 in neuroendocrine (merkel cell) carcinoma of the skin by competitive RT-PCR. Endocrine Pathology, 1999, 10, 37-46.	9.0	16
207	AgNOR quantity as a prognostic tool in hyperplastic and neoplastic parathyroid glands. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2000, 437, 298-303.	2.8	16
208	Pathological Characterization of Tumor Immune Microenvironment (TIME) in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2564.	3.7	16
209	A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 396-407.	9.0	16
210	Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes ll̂Bl̂± mediated p53 nuclear exclusion. Oncotarget, 2015, 6, 25217-25225.	1.8	16
211	CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype. Oncotarget, 2015, 6, 29626-29636.	1.8	16
212	MET mutations are associated with aggressive and radioresistant brain metastatic non-small-cell lung cancer: Table 1 Neuro-Oncology, 2016, 18, 598-599.	1.2	15
213	Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma. Endocrine Pathology, 2017, 28, 95-102.	9.0	15
214	Ghrelin and Tumors. Endocrine Development, 2013, 25, 122-134.	1.3	14
215	Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas. International Journal of Surgical Pathology, 2014, 22, 401-407.	0.8	14
216	YKL-40/c-Met Expression in Rectal Cancer Biopsies Predicts Tumor Regression following Neoadjuvant Chemoradiotherapy: A Multi-Institutional Study. PLoS ONE, 2015, 10, e0123759.	2.5	14

#	Article	IF	Citations
217	Malignant pleural mesothelioma: Germline variants in DNA repair genes may steer tailored treatment. European Journal of Cancer, 2022, 163, 44-54.	2.8	14
218	Mesothelioma families without inheritance of a BAP1 predisposing mutation. Cancer Genetics, 2016, 209, 381-387.	0.4	13
219	The International Association for the Study of Lung Cancer Global Survey on Programmed Death-Ligand 1 Testing for NSCLC. Journal of Thoracic Oncology, 2021, 16, 686-696.	1.1	13
220	Real-World Data on NGS Diagnostics: a survey from the Italian Society of Pathology (SIAPeC) NGS Network. Pathologica, 2021, 113, 262-271.	3.4	13
221	Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines. Oncotarget, 2016, 7, 76577-76589.	1.8	13
222	Spectrum of Kidney Injury Following COVID-19 Disease: Renal Biopsy Findings in a Single Italian Pathology Service. Biomolecules, 2022, 12, 298.	4.0	13
223	Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 451, 729-736.	2.8	12
224	Interpathologist concordance in the histological diagnosis of focal prostatic atrophy lesions, acute and chronic prostatitis, PIN, and prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 711-715.	2.8	12
225	Karpinski Score under Digital Investigation: A Fully Automated Segmentation Algorithm to Identify Vascular and Stromal Injury of Donors' Kidneys. Electronics (Switzerland), 2020, 9, 1644.	3.1	12
226	Malignant struma ovarii: next-generation sequencing of six cases revealed Nras, Braf, and Jak3 mutations. Endocrine, 2021, 71, 216-224.	2.3	12
227	Protective Role of the M-Sec–Tunneling Nanotube System in Podocytes. Journal of the American Society of Nephrology: JASN, 2021, 32, 1114-1130.	6.1	12
228	INSM1 Expression in Breast Neoplasms with Neuroedocrine Features. Endocrine Pathology, 2021, 32, 452-460.	9.0	12
229	Surgical margin status of specimen and oncological outcomes after laparoscopic radical prostatectomy: experience after 400 procedures. World Journal of Urology, 2012, 30, 245-250.	2.2	11
230	Pathological prognostic markers in central nervous system solitary fibrous tumour/hemangiopericytoma: Evidence from a small series. PLoS ONE, 2018, 13, e0203570.	2.5	11
231	Predictor Analysis in Radiofrequency Ablation of Benign Thyroid Nodules: A Single Center Experience. Frontiers in Endocrinology, 2021, 12, 638880.	3.5	11
232	Oxyphilic and non-oxyphilic thyroid carcinoma cell lines differ in expressing apoptosis-related genes. Journal of Endocrinological Investigation, 2003, 26, 660-667.	3.3	10
233	Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas. Tumor Biology, 2017, 39, 101042831769431.	1.8	10
234	Exploring the Prognostic Role of Ki67 Proliferative Index in Merkel Cell Carcinoma of the Skin: Clinico-Pathologic Analysis of 84 Cases and Review of the Literature. Endocrine Pathology, 2020, 31, 392-400.	9.0	10

#	Article	IF	CITATIONS
235	Oncogenic properties and signaling basis of the PAX8â€GLIS3 fusion gene. International Journal of Cancer, 2020, 147, 2253-2264.	5.1	10
236	Diagnostic Value of Conventional PET Parameters and Radiomic Features Extracted from 18F-FDG-PET/CT for Histologic Subtype Classification and Characterization of Lung Neuroendocrine Neoplasms. Biomedicines, 2021, 9, 281.	3.2	10
237	mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. Oncoscience, 2015, 2, 382-394.	2.2	10
238	Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome. Journal of Neuropathology and Experimental Neurology, 2019, 78, 248-256.	1.7	10
239	Current State-of-the-Art Therapy for Advanced Squamous Cell Lung Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , 354-358.	3.8	9
240	Management of Progressive Pulmonary Nodules FoundÂduring and outside of CT Lung Cancer Screening Studies. Journal of Thoracic Oncology, 2017, 12, 1755-1765.	1.1	9
241	Adrenal Rests in the Uro-genital Tract of an Adult Population. Endocrine Pathology, 2021, 32, 375-384.	9.0	9
242	Safe transportation of formalin-fixed liquid-free pathology specimens. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 473, 105-113.	2.8	8
243	The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression Profile. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4577-e4592.	3.6	8
244	A combined glucagonoma and VIPoma syndrome: First pathologic and clinical report. Cancer, 1988, 62, 2576-2579.	4.1	7
245	$34\hat{l}^2$ E12 Cytokeratin Immunodetection in the Differential Diagnosis of Neuroendocrine Carcinomas of the Breast. Applied Immunohistochemistry and Molecular Morphology, 2001, 9, 229-233.	1.2	7
246	Title is missing!. Applied Immunohistochemistry & Molecular Morphology, 2001, 9, 229-233.	2.0	7
247	Classic and Recent Special Stains Used in Differential Diagnosis of Endocrine Tumors. Endocrine Pathology, 2001, 12, 379-388.	9.0	7
248	DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer. Clinical Epigenetics, 2019, 11, 152.	4.1	7
249	DNA Methylation Profiling Discriminates between Malignant Pleural Mesothelioma and Neoplastic or Reactive Histologic Mimics. Journal of Molecular Diagnostics, 2021, 23, 834-846.	2.8	7
250	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. Cancers, 2021, 13, 4875.	3.7	7
251	Recent advances and current controversies in lung neuroendocrine neoplasms✰. Seminars in Diagnostic Pathology, 2021, 38, 90-97.	1.5	7
252	Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel. Biomedicines, 2021, 9, 1318.	3.2	7

#	Article	IF	CITATIONS
253	The Adverse Impact of the COVID-19 Pandemic on Abdominal Emergencies: A Retrospective Clinico-Pathological Analysis. Journal of Clinical Medicine, 2021, 10, 5254.	2.4	7
254	SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 75.	8.6	7
255	mEPE-score: a comprehensive grading system for predicting pathologic extraprostatic extension of prostate cancer at multiparametric magnetic resonance imaging. European Radiology, 2022, 32, 4942-4953.	4.5	7
256	Molecular Subtypes of Extra-pulmonary Neuroendocrine Carcinomas Identified by the Expression of Neuroendocrine Lineage-Specific Transcription Factors. Endocrine Pathology, 2022, 33, 388-399.	9.0	7
257	Dissecting morphological and molecular heterogeneity in adrenocortical carcinoma. Turk Patoloji Dergisi, 2015, 31 Suppl 1, 98-104.	0.3	6
258	Prognostic role of PD-L1 and immune-related gene expression profiles in giant cell tumors of bone. Cancer Immunology, Immunotherapy, 2020, 69, 1905-1916.	4.2	6
259	Pituitary metastases from neuroendocrine neoplasms: case report and narrative review. Pituitary, 2021, 24, 828-837.	2.9	6
260	Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. ESMO Open, 2016, 1, e000118.	4.5	6
261	Immunohistochemical study of neuroendocrine differentiation in primary glandular lesions and tumors of the urinary bladder., 2005, 27, 218-24.		6
262	NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal of Thoracic Oncology, 2022, 17, 793-805.	1.1	6
263	Safety and diagnostic performance of image-guided lung biopsy in the targeted therapy era. Radiologia Medica, 2015, 120, 1024-1030.	7.7	5
264	Analysis of histological and immunohistochemical patterns of benign and malignant adrenocortical tumors by computerized morphometry. Pathology Research and Practice, 2017, 213, 815-823.	2.3	5
265	High miR-100 expression is associated with aggressive features and modulates TORC1 complex activation in lung carcinoids. Oncotarget, 2018, 9, 27535-27546.	1.8	5
266	Development and internal validation of a predictive model for the estimation of pheochromocytoma recurrence risk after radical surgery. European Journal of Endocrinology, 2022, 186, 399-406.	3.7	5
267	Poorly Differentiated Carcinoma of the Thyroid Gland. , 2009, 14, 219-223.		4
268	Mitochondrial DNA "common deletion―in post–fine needle aspiration infarcted oncocytic thyroid tumors. Human Pathology, 2017, 69, 23-30.	2.0	4
269	Primary Thymic Signet Ring Cell Adenocarcinoma: A Currently Unrecognized Variant. International Journal of Surgical Pathology, 2019, 27, 315-321.	0.8	4
270	Clinical implications of lung neuroendocrine neoplasm classification. Expert Review of Anticancer Therapy, 2021, 21, 377-387.	2.4	4

#	Article	IF	CITATIONS
271	Radiofrequency Thermal Ablation for a Small Papillary Thyroid Carcinoma in a Patient Unfit for Surgery: A Case Report. Frontiers in Endocrinology, 2021, 12, 566362.	3.5	4
272	Intron 4–5 hTERT DNA Hypermethylation in Merkel Cell Carcinoma: Frequency, Association with Other Clinico-pathological Features and Prognostic Relevance. Endocrine Pathology, 2021, 32, 385-395.	9.0	4
273	Evaluation of the Preclinical Efficacy of Lurbinectedin in Malignant Pleural Mesothelioma. Cancers, 2021, 13, 2332.	3.7	4
274	Anti-CD37 Alpha-Amanitin Conjugated Antibodies As Therapeutic Weapons for Richter's Syndrome. Blood, 2021, 138, 791-791.	1.4	4
275	Renal Involvement in Transthyretin Amyloidosis: The Double Presentation of Transthyretin Amyloidosis Deposition Disease. Nephron, 2022, 146, 481-488.	1.8	4
276	Images in Endocrine Pathology: Unique Composite Adrenal Adenomatoid Tumor, Ganglioneuroma, Myelolipoma, and Cortical Nodular Hyperplasia. Endocrine Pathology, 2017, 28, 276-279.	9.0	3
277	Differential Expression Profiles of Cell-to-Matrix-Related Molecules in Adrenal Cortical Tumors: Diagnostic and Prognostic Implications. Journal of Personalized Medicine, 2021, 11, 378.	2.5	3
278	Amyloid-Rich Pancreatic Neuroendocrine Tumors: a Potential Diagnostic Pitfall in Endoscopic Ultrasound–Guided Fine Needle Aspiration Cytology (EUS-FNAC). Endocrine Pathology, 2021, 32, 318-325.	9.0	3
279	Small-Cell Carcinoma of the Lung: What We Learned about It?. Acta Cytologica, 2021, , 1-12.	1.3	3
280	From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of Pheochromocytoma. Biomedicines, 2022, 10, 1310.	3.2	3
281	Proliferative activity of oxyphilic (Hurthle) cells in reactive and neoplastic thyroid lersions. Endocrine Pathology, 1999, 10, 173-179.	9.0	2
282	Management of Patients with Castration-Resistant Prostate Cancer (CRPC): Results of an Italian Survey Using the Delphi Method. Tumori, 2016, 102, 514-520.	1.1	2
283	CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoidsÂ- a short report. Cellular Oncology (Dordrecht), 2018, 41, 687-691.	4.4	2
284	Multiple Assays to Determine Methylguanine-Methyltransferase Status in Lung Carcinoids and Correlation with Clinical and Pathological Features. Neuroendocrinology, 2020, 110, 1-9.	2.5	2
285	Retrospective analysis of the ultrasound features of resected thyroid nodules. Endocrine, 2021, 72, 486-494.	2.3	2
286	SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas. Journal of Thoracic Oncology, 2021, 16, e32-e35.	1.1	2
287	Merkel Cell Carcinomas: Expression of S-Phase Kinase-Associated Protein 2 (Skp2), p27, and Proliferation Markers. Endocrine Pathology, 2003, 14, 221-230.	9.0	2
288	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: From Echography to Genetic Profile. Tohoku Journal of Experimental Medicine, 2020, 252, 209-218.	1.2	2

#	Article	IF	Citations
289	Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas Focusing on Tumor-Infiltrating Lymphocytes, MCPYV Infection and ALK Expression. Endocrine Pathology, 2022, 33, 289-303.	9.0	2
290	Ghrelin and Tumors. , 2004, , 143-164.		1
291	ALK expression favorably impacts the prognosis of NRAS‑mutated metastatic melanomas. Oncology Letters, 2018, 16, 7091-7096.	1.8	1
292	Detection of Angiotensin II type lâ€receptor antibodies in transplant glomerulopathy. Clinical Transplantation, 2018, 32, e13407.	1.6	1
293	Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas. Vaccines, 2020, 8, 166.	4.4	1
294	Primary lung adenocarcinoma in three adolescent patients affected by bone sarcomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1125-1134.	2.8	1
295	Caveolin-1 expression predicts favourable outcome and correlates with PDGFRA mutations in gastrointestinal stromal tumours (GISTs). Journal of Clinical Pathology, 2021, , jclinpath-2021-207595.	2.0	1
296	Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, , 1.	2.8	1
297	<scp>MicroRNA</scp> profiling predicts positive nodal status in papillary thyroid carcinoma in the preoperative setting. Cancer Cytopathology, 2022, , .	2.4	1
298	Glutathione S-transferase T1 and M1 polymorphisms and risk of thyroid neoplasms. Archive of Oncology, 2003, $11$ , $185-185$ .	0.2	0
299	Neuroendocrine Differentiation Patterns in Various Organs (Including Lung, Breast, Skin and) Tj ETQq1 1 0.78431	.4 rgBT /C	)verlock 10 Ti
300	Histologic and genotypic re-evaluation of non-small cell lung cancer (NSCLC): A monocentric study Journal of Clinical Oncology, 2014, 32, e19083-e19083.	1.6	0
301	Next-generation sequencing in malignant pleural mesothelioma: A retrospective study Journal of Clinical Oncology, 2014, 32, 7530-7530.	1.6	0
302	Differential thymidylate synthase expression in lung cancer adenocarcinoma subtypes Journal of Clinical Oncology, 2014, 32, e18539-e18539.	1.6	0
303	TREM-1 expression in HPV related oropharyngeal squamous cell carcinoma (OP-SCC) Journal of Clinical Oncology, 2018, 36, e18037-e18037.	1.6	0
304	Reply to: Oncologic thoracic surgery during the second wave of COVIDâ€19 pandemic: How to be ready for the storm. Journal of Surgical Oncology, 2021, 123, 1169-1169.	1.7	0
305	Eccrine spiradenoma of the nipple: Case report, differential diagnosis and literature review. Histology and Histopathology, 2019, 34, 909-915.	0.7	0